Evaluating metabolites in patients with major depressive disorder who received mindfulness-based cognitive therapy and healthy controls using short echo MRSI at 7 Tesla. by Li, Yan et al.
UCSF
UC San Francisco Previously Published Works
Title
Evaluating metabolites in patients with major depressive disorder who received 
mindfulness-based cognitive therapy and healthy controls using short echo MRSI at 7 
Tesla.
Permalink
https://escholarship.org/uc/item/4937p2nr
Journal
Magma (New York, N.Y.), 29(3)
ISSN
0968-5243
Authors
Li, Yan
Jakary, Angela
Gillung, Erin
et al.
Publication Date
2016-06-01
DOI
10.1007/s10334-016-0526-7
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1 3
Magn Reson Mater Phy (2016) 29:523–533
DOI 10.1007/s10334-016-0526-7
RESEARCH ARTICLE
Evaluating metabolites in patients with major depressive disorder 
who received mindfulness‑based cognitive therapy and healthy 
controls using short echo MRSI at 7 Tesla
Yan Li1 · Angela Jakary1 · Erin Gillung2 · Stuart Eisendrath2 · Sarah J. Nelson1,3 · 
Pratik Mukherjee1 · Tracy Luks1 
Received: 15 October 2015 / Revised: 5 January 2016 / Accepted: 6 January 2016 / Published online: 9 February 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
of N-acetyl aspartate (NAA)/tCr in the left ACC, myo-
inositol/tCr in the right insula, and glutathione/tCr in the 
left putamen were significantly decreased. At baseline, the 
severity of depression was negatively correlated with my-
inositol/tCr in the left insula and putamen. The improve-
ment in depression severity was significantly associated 
with changes in NAA/tCr in the left ACC.
Conclusions This study has successfully evaluated 
regional differences in metabolites for patients with MDD 
who received MBCT treatment and in controls using 7 
Tesla MRSI.
Keywords Major depressive disorder · MBCT · Magnetic 
resonance spectroscopic imaging · 7 Tesla
Introduction
Major depressive disorder (MDD) affects about 6.7 % of the 
adults in the United States per year and is the leading cause of 
disability for people from 15 to 44 years old. The most com-
mon treatments include antidepressant medications and psy-
chotherapy. Most patients with MDD have recurrent episodes 
and often experience treatment failure under current thera-
pies, which severely impact their quality of life. Mindfulness-
based cognitive therapy (MBCT), a method for integrating 
cognitive behavioral therapy with mindfulness meditation, 
teaches patients how to disengage from habitual “automatic” 
dysfunctional cognitive routines, in particular depression-
related ruminative thought patterns. MBCT was first used 
for preventing the relapse of depression [1] and has shown 
its efficacy in reducing depressive recurrence [2] and treat-
ing acute [3], chronic [4], and treatment-resistant depression 
[5] as an augmentation. These findings make MBCT treat-
ment a potential valuable stand-alone treatment for MDD.
Abstract 
Objectives Our aim was to evaluate differences in metab-
olite levels between unmedicated patients with major 
depressive disorder (MDD) and healthy controls, to assess 
changes in metabolites in patients after they completed 
an 8-week course of mindfulness-based cognitive therapy 
(MBCT), and to exam the correlation between metabolites 
and depression severity.
Materials and methods Sixteen patients with MDD and 
ten age- and gender-matched healthy controls were stud-
ied using 3D short echo-time (20 ms) magnetic resonance 
spectroscopic imaging (MRSI) at 7 Tesla. Relative metabo-
lite ratios were estimated in five regions of interest corre-
sponding to insula, anterior cingulate cortex (ACC), cau-
date, putamen, and thalamus.
Results In all cases, MBCT reduced severity of depres-
sion. The ratio of total choline-containing compounds/
total creatine (tCr) in the right caudate was significantly 
increased compared to that in healthy controls, while ratios 
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Although the etiology and neuropathology of MDD 
is still not fully understood, it is thought to be associ-
ated with chemical changes that involve multiple brain 
circuits. Proton magnetic resonance spectroscopy 
(MRS) is a powerful tool for noninvasively investigat-
ing brain metabolism. Spectra acquired with long echo 
times (TEs) provide estimates of metabolite levels, such 
as total choline-containing compounds (tCho, reflect-
ing membrane synthesis), total creatine (tCr, reflect-
ing cellular bioenergetics), and N-acetyl aspartate 
(NAA, a neuronal marker). At short TEs, metabolites 
such as myo-inositol (mI), glutamate (Glu), and glu-
tamine (Gln) also appear, but overlap between peaks 
can make it difficult to obtain accurate quantification. 
Spectral editing methods using J-coupling differences 
allow unobstructed detection of glutathione (GSH) and 
γ-aminobutyric acid (GABA) but require acquisition 
from a relatively large region and/or relatively long 
acquisition time. High field MR systems, such as 7 
Tesla (7T) scanners, offer advantages in higher signal-
to-noise ratio (SNR) and enhanced spectral quantifica-
tion for all of these metabolites [6]. Other brain metab-
olites, such as N-acetyl-aspartyl glutamate (NAAG), 
glycine (Gly), and glucose that have much lower con-
centration and/or overlap with the major peaks, can also 
be detected at high field using ultrashort TE (≤10 ms) 
MRS or TE-optimized sequences [7–9].
Multiple studies using single-voxel and spectroscopic 
imaging have been performed at lower field strengths in 
patients with MDD and have reported regional and/or 
global metabolite differences. Although the overall consen-
sus is that there is hypometabolism in patients compared to 
healthy controls, there was some variability in the results 
obtained [10]. Efficacy of other MDD treatments was 
evaluated using MRS in different brain regions. Changes 
in metabolites, such as Glu, NAA, and tCho, were found 
to be correlated with response to pharmacotherapy or anti-
depressant stimulation techniques [11]. Regions of inter-
est (ROI) for these studies involved locations in the basal 
ganglia, limbic system, frontal cortex, and occipital cortex. 
Multivoxel 3D magnetic resonance spectroscopic imaging 
(MRSI) is of interest because it allows characterization of 
the spatial extent and metabolic properties within multiple 
regions of the brain.
The purpose of this study was to compare relative levels 
of metabolites between unmedicated patients with MDD 
and healthy controls, to evaluate the relationship between 
metabolite levels and disease severity, and to examine the 
association between changes in metabolite levels and the 
outcome of completed MBCT treatment for these patients 
using 3D short echo-time MRSI at 7T. The patient popu-
lation comprised a subset of individuals who participated 
in a previously published project designed to evaluate the 
efficacy of treatment based upon standard clinical criteria 
[12]. ROIs within the basal ganglia, limbic system, and 
frontal cortex were selected for analysis because they have 
been identified as being relevant for studying psychiatric 
diseases previously.
Materials and methods
Study population
Sixteen depressed patients (11 F/5 M, 30 ± 7 years) who 
met the Diagnostic and Statistical Manual of Mental Dis-
orders, Fourth Edition (DSM-IV) criteria for MDD and 
who had been medication free for at least 6 weeks, and 
ten age- and gender-matched healthy controls (7 F/3 M, 
32 ± 9 years) who had no history of neurologic illness, 
traumatic brain injury, or DSM-IV Axis I or II diagnosis 
were recruited into this study. Individuals with alcohol or 
substance abuse or dependence within the last 3 months, 
inadequate English language comprehension, or significant 
medical conditions or contraindications to MR systems 
were excluded, as were individuals who currently medi-
tated once or more a week or who practiced yoga twice or 
more per week.
Each participant was given written informed consent in 
accordance with the University of California San Francisco 
(UCSF) IRB procedures. Baseline and post-MBCT MRSI 
data were successfully acquired from nine patients. Five 
additional patients had baseline MRSI data only. Among 
these five patients, two dropped out of the study during 
MBCT treatment, one declined to participate in the post-
MBCT MR scans, and two became pregnant during MBCT 
treatment. Two patients only had post-MBCT MRSI scans 
for purely logistical reasons.
Depressive symptoms were evaluated using the Hamil-
ton Depression Severity Rating 17-item scale (HAMD-17) 
in all participants at baseline. Fourteen of the 16 patients 
completed the manual and were reassessed using the 
HAMD-17 within 2 weeks of completing treatment (post-
MBCT). Remission was identified by scores ≤7 on the 
post-MBCT HAMD-17, and the reduction rate was cal-
culated by changes between baseline and post-MBCT 
HAMD-17 scores divided by the baseline scores.
Mindfulness‑based cognitive therapy (MBCT) methods
MBCT treatment consisted of 8 weekly classes each last-
ing 2.25 h, and participants were also asked to complete 
45 min of homework 6 days per week. This 8-week MBCT 
group intervention used a clinician and participant manual 
developed by Segal et al. [13] with modifications for cur-
rent depression, and was described in Eisendrath et al. [14].
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MR acquisitions
All MR scans were performed using a 32-channel 
receive-only array with a volume-transmit head coil 
(NOVA Medical, Wilmington, MA, USA) on a GE 7T 
MR950 scanner (GE Healthcare, Waukesha, WI, USA). 
Anatomical imaging consisted of a T1-weighted sag-
ittal scout (TR/TE = 6/2 ms), 3D T1-weighted inver-
sion recovery-prepared spoiled gradient echo (IR SPGR) 
[TR/TE/inversion time (TI) = 6/2/600 ms, matrix 
size = 256 × 256 × 192 FOV = 256 × 256 × 192 mm3, 
voxel size = 1 × 1 × 1 mm3), and 3D T2-weighted fast 
spin echo (FSE-Cube) (TR/TE = 6000/60 ms, matrix 
size = 512 × 512, FOV = 256 × 256 mm2, voxel 
size = 0.5 × 0.5 mm2, slice thickness/overlap = 2/1 mm, 
acceleration factor = 3) images.
Optimization of high order shimming and transmit 
gains were performed prior to spectral data acquisitions. 
3D H-1 MRSI was obtained using spectrally selective 
adiabatic inversion recovery lipid suppression, chemi-
cal shift selective (CHESS) water suppression, automati-
cally prescribed very selective suppression (VSS) outer 
volume suppression, and spin-echo slice selection with 
TE/TR = 20/2000 ms, spectra array = 16–20 × 22 × 8, 
and nominal spatial resolution = 1 cm3 [15]. Total acqui-
sition time was 8.77 min for 16 × 22 × 8 or 10.96 min 
for 20 × 22 × 8 spectral arrays when applying an inter-
leaved flyback echo-planar trajectory [16] in the anterior/
posterior direction of the FOV. Slice direction of spectra 
data was placed parallel to the anterior commissure (AC)–
posterior commissure (PC) line with full coverage of the 
thalamus (Fig. 1a). The variation in radio-frequency (RF) 
excitation due to B1 inhomogeneities was minimized by 
adjusting both the transmitter gain and relative RF power 
of CHESS, 90°, and 180° pulses.
MR postprocessing
Postprocessing was performed using a previously pub-
lished methodology [15]. Spectral arrays acquired with the 
interleaved flyback readout trajectory were combined and 
reordered to a rectilinear grid [16], processed with phase 
and frequency corrections individually for each coil, com-
bined by weighting with coil sensitivities, and then quanti-
fied using LCModel [17]. Metabolite signals for the basis 
set were generated using NMR-SCOPE [18] with prior 
knowledge of chemical shift and J-coupling information 
[19]. Only those voxels with relative Cramer–Rao lower 
bounds (CRLBs) <10 % for tCho, tCr, and NAA, and 20 % 
for Glu, Gln, GABA, mI, Gly, and GSH, were included in 
the analysis.
The 3D MRSI data were referenced to the 3D 
T1-weighted images by assuming that there was no 
movement between the two acquisitions. Segmentation of 
the brain was performed automatically on these images 
using Harvard–Oxford cortical and subcortical structural 
atlases [20, 21]. ROIs used in the analysis of the 3D MRSI 
consisted of insula, medial frontal gyrus (MFG), anterior 
cingulate cortex (ACC), caudate, putamen, pallidum, and 
thalamus. The segmented ROIs were then aligned to the 
orientation of the 3D MRSI and down-sampled to the reso-
lution of spectral data. Median metabolite ratios from vox-
els overlapping by at least 40 % with the anatomical ROIs 
were included in the analysis. An example of ROIs overlaid 
on the 3D T1-weighted images is shown in Fig. 1a. The 
signal from the MFG was partially suppressed by the outer-
volume suppression bands; the small size of the pallidum 
meant that overlapping voxels may contain a relatively high 
portion of other tissue. These two regions were therefore 
excluded from further analysis. The remaining five ROIs 
were analyzed and divided into right- and left-hemisphere 
sides.
Statistics
Statistical analysis was performed using R (www.r-project.
org). Given the small sample size of the study popula-
tion, nonparametric statistic methods were used for data 
analysis, and the number of participants in each group 
was required to be more than seven. Adjustment for mul-
tiple comparisons was not performed due to the explora-
tory nature of the study. A p value of <0.05 was consid-
ered as significant at this stage. Wilcoxon signed-rank tests 
were used to test differences in HAMD-17 scores between 
baseline and post-MBCT evaluations. Differences in base-
line metabolite ratios between patients and controls were 
assessed using Wilcoxon rank-sum tests, and the effects 
of MBCT on metabolite ratios were assessed using Wil-
coxon signed-rank tests. Spearman rank-correlation coeffi-
cients were calculated to determine the association between 
baseline metabolite ratios and baseline HAMD-17 scores, 
between baseline metabolite ratios and reduction rates 
on HAMD-17 scores, and between changes in metabolite 
ratios and reduction rates in HAMD-17 scores.
Results
Participant characteristics and treatment outcomes
The characteristics of study participants are summarized 
in Fig. 2, which also shows changes in HAMD-17 in all 
patients. At baseline, the median HAMD-17 for patients 
was 18 (range 13–24) and declined to 8 (range 2–18) 
after the 8-week MBCT treatment. All 14 patients who 
completed the MBCT treatment demonstrated reduced 
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HAMD-17 scores, six achieved remission, and eight had a 
reduction on the HAMD-17 score >50 %. The difference 
in HAMD-17 scores between baseline and post-MBCT was 
highly significant (p < 0.001).
MR characteristics
The presence of obvious imaging abnormalities was ruled 
out based on FSE-Cube images by a neuroradiologist. An 
4.0                                            3.0                                            2.0
Chemical Shift (ppm)
NAA
Glu
tCr
tChotCr-CH2
GABA
Glx
mI
GSH
Glu CRLB = 8%
Gln CRLB = 19%
GSH CRLB = 8%
GABA CRLB = 12%
a
b
Fig. 1  a Location of 3D magnetic resonance spectroscopic imag-
ing (MRSI) prescription and regions of interest (ROIs) that were 
segmented using Harvard–Oxford cortical and subcortical atlases, 
inversely transformed from the MNI space and then resampled to the 
resolution of spectra overlaid on T1-weighted images. b MRSI data 
(with baseline between 1.6 and 4.2 ppm) from a patient with major 
depressive disorder (MDD) and an example of fitted spectra from 
LCModel in the selected voxel
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example of 3D MRSI data from a patient and the ROIs 
segmented using the Harvard–Oxford cortical and subcor-
tical structural atlases are illustrated in Fig. 1b. Note that 
the baseline was not removed from the spectra shown and 
that the CRLB estimates of reliability of Glu, GSH, and mI 
measures obtained from LCModel were relatively small.
Differences in metabolite ratios between groups
Figure 3 summarizes ROIs that had significant differences 
in metabolite ratios between groups. No differences were 
detected in the thalamus.
Table 1 gives median and interquartile range (IQR) 
for tCho/tCr, NAA/tCr, mI/tCr, Glu/tCr, GABA/tCr, and 
GSH/tCr in each ROI from patients and controls at base-
line. When compared to values in controls, metabolite 
ratio levels of the following were significantly lower at 
baseline in patients: mI/tCr in the right insula [patients vs. 
controls, mean ± standard deviation (SD), 0.60 ± 0.07 
vs. 0.66 ± 0.06, p = 0.042], GSH/tCr in the left puta-
men (0.23 ± 0.06 vs. 0.28 ± 0.05, p = 0.044), NAA/tCr 
in the left ACC (1.27 ± 0.14 vs. 1.41 ± 0.21, p = 0.044). 
The level of tCho/tCr in the right caudate (0.26 ± 0.07 vs. 
0.21 ± 0.07, p = 0.041) was significantly higher at base-
line in patients with MDD than in controls.
Table 2 demonstrates median and IQR of tCho/tCr, 
NAA/tCr, mI/tCr, Glu/tCr, GABA/tCr, and GSH/tCr 
from patients at baseline and post-treatment. After com-
pleting MBCT treatment, the levels of NAA/tCr in the 
left ACC were significantly increased (1.26 ± 0.10 vs. 
1.42 ± 0.17, signed-rank, p = 0.018). Although tCho/
tCr in the right caudate (0.25 ± 0.06 vs. 0.20 ± 0.02, 
signed-rank, p = 0.084) were not significantly different 
from that at baseline in patients who had both baseline 
and post-MBCT MRSI scans (nine patients), they were 
statistically decreased (0.26 ± 0.07 vs. 0.19 ± 0.02, rank-
sum, p = 0.004) when comparing all patients between 
baseline and post-MBCT (14 vs. 11 patients). Glu/tCr in 
the left caudate (0.93 ± 0.18 vs. 1.09 ± 0.14, rank-sum, 
p = 0.026), mI/tCr in right caudate (0.62 ± 0.14 vs. 
0.48 ± 0.07, rank-sum, p = 0.017), and tCho/tCr in the 
right putamen (0.22 ± 0.04 vs. 0.18 ± 0.02, rank-sum, 
p = 0.011) were also significantly different from baseline 
to post-treatment.
Correlations between metabolite ratios and HAMD‑17 
scores
Figure 4 shows the regions in which there were signifi-
cant associations between metabolite ratios and HAMD-
17 scores. Higher HAMD-17 scores at baseline were sig-
nificantly associated with lower levels of mI/tCr in the 
left insula (correlation coefficient, r = −0.59, p = 0.026, 
25
20
15
10
  5
  0 Baseline                                                   Post-MBCT
Baseline MRSI only
Post-MBCT MRSI only
Two MRSI scans 
HA
MD
-1
7
                                                 MDD Patients        Health Controls
Number of subjects                          16                            10
Age (years)                                   30.2±6.7                  32.1±8.8
Education (years)                        14.9±2.2                  17.6±2.1*
HAMD-17  Scores             19.3±3.5      8.4±3.7**        1.3±1.0*
                  Reduction Rate      57.2±17.2%**
* 1 subject had unknow information
** 2 patients dropped out of the study
Fig. 2  Characteristics of study participants. Age, education, and 
Hamilton Depression Severity Rating 17-item scale (HAMD-17) 
scores are summarized for patients and healthy controls. All patients 
demonstrated reduced HAMD-17 scores after completing mindful-
ness-based cognitive therapy (MBCT). HAMD-17 scores for those 
who did or did not have 3D magnetic resonance spectroscopic imag-
ing (MRSI) scans are shown in different shapes of markers
HC
MDD at baseline
MDD at baseline (paired)
MDD post-MBCT (paired)
MDD post-MBCT
tCho/tCr              Glu/tCr                mI/tCr             GSH/tCr             NAA/tCr
R Caudate          L Caudate            R Insula         L Putamen            L ACC
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
 <0.05
Fig. 3  Significant differences in metabolite ratios between patients 
with major depressive disorders (MDD) and controls at baseline and 
between patients at baseline and after mindfulness-based cognitive 
therapy (MBCT) in the R caudate, L caudate, R insula, L putamen, 
and L anterior cingulate cortex (ACC). (R right; L left)
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N = 14) and left putamen (r = −0.65, p = 0.021, N = 12) 
at baseline. Increases in NAA/tCr from baseline to post-
MBCT were significantly associated with a reduction in 
HAMD-17 scores after completing MBCT in the left ACC 
(r = −0.93, p = 0.002, N = 8).
Discussion
This study has successfully demonstrated the application 
of 7T H-1 MRSI to healthy controls and to patients with 
MDD before and after treatment with MBCT. As reported 
by Eisendrath et al. [12] for the larger study that our popu-
lation was drawn from, MBCT greatly reduced the severity 
of depression. Changes in metabolite levels after complet-
ing MBCT treatment, and the correlation between metabo-
lite levels and depression severity are of interest for future 
use in evaluating individuals who may benefit from this or 
other, similar therapies. The main finding in this respect is 
that differences in metabolite ratios observed in patients 
at baseline were normalized after treatment and became 
similar to the levels in healthy controls. To our knowledge, 
this is the first study showing differences in metabolites in 
patients with MDD who were treated with MBCT alone.
The improved sensitivity and spectral resolution of the 
7T scanner is important for optimizing data quality using 
in vivo MRSI [8, 22]. The method used in this study to 
estimate metabolite levels was demonstrated previously 
and has been applied in other patient populations [15]. To 
avoid the time penalty of acquiring an additional 3D MRSI 
acquisition with unsuppressed water for scaling metabolite 
signals, we chose to reference levels of the metabolites of 
interest to the levels of tCr in the same voxel. Prior studies 
have shown that these acquisition and postprocessing meth-
ods are able to provide uniform and reliable quantification 
in the entire spectral array for metabolite ratios, including 
tCho/tCr, NAA/tCr, Glu/tCr, Gln/tCr, GSH/tCr, mI/tCr, 
Gly/tCr, and GABA/tCr, within a clinically reasonable total 
acquisition time of ~10 min [15].
Previous studies evaluating metabolites in MDD used a 
single-voxel MRS acquisition with a large voxel size and pro-
duced variable results [10]. This may be due to differences 
in the patient population or in tissue components studied and 
the degree of partial volume that was present. Multi-voxel 
3D MRSI has the advantage of providing an assessment of 
spatial distribution of metabolites. In this study, 3D MRSI 
was prescribed within a 4-cm excitation slab that was paral-
lel to the AC-PC line and had full coverage of the thalamus. 
Five types of ROIs were defined within frontal and limbic 
lobes, insular and subcortical regions. The apriori selection of 
ROIs was limited by the position of the excitation slab such 
that the cortex was partially suppressed by the eight automati-
cally prescribed outer-volume lipid suppression and the spa-
tial resolution (1 cm3) used for data acquisition (see Fig. 1). 
In an attempt to provide robust measures, we used median 
metabolite levels from voxels that overlapped by at least 40 % 
with the anatomic ROIs being considered.
The tCho peak resonates at 3.22 ppm at in vivo spec-
trum and includes signals from Cho, phosphocholine, 
glycerophosphocholine, and acetylcholine. Previous 
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Fig. 4  Significant associations between metabolite ratios and Ham-
ilton Depression Severity Rating 17-item scale (HAMD-17) scores 
at baseline in patients (top, middle) and between percent changes on 
metabolite ratios and reduction on HAMD-17 scores after completing 
MBCT (bottom). The correlation coefficients and p values were cal-
culated using Spearman rank tests
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studies showed that the level of tCho/tCr was increased 
in the basal ganglion in patients with MDD [23, 24] and 
that it decreased with antidepressant treatment (nefazo-
done) [23]. This is consistent with our findings of sig-
nificantly increased tCho/tCr in the right caudate in 
MDD, which decreased to levels in controls after com-
pleting MBCT treatment. Although an elevation of tCho/
tCr in the basal ganglia has been reported after 8 weeks 
of fluoxetine treatment in patients who responded to the 
therapy [25], no controls were included in that study. 
Elevated tCho is thought to be associated with increased 
cell density and/or membrane turnover. The alteration 
in tCho observed in our study suggests abnormalities in 
myelination [26] and/or glial function [27], which are 
associated with MDD, and/or altered cellular signal-
transduction pathways.
NAA is found only in the brain and spinal cord and is 
synthesized and stored in neurons but hydrolyzed in oligo-
dendrocytes. Since NAA is a neuronal marker, any pathol-
ogy with a loss of neurons or function results in reduced 
NAA levels. Vythilingam et al. [24] reported significantly 
decreased NAA/tCr in the caudate in patients with MDD. 
NAA has also been studied in the ACC and the frontal lobe 
in patients with MDD [28–30], and prior observed that 
lower NAA in the ACC and decreased NAA/tCr in the MFG 
at baseline were normalized after antidepressant treatment 
[30, 31]. This is similar to our results for patients who com-
pleted MBCT treatment. Normalization of NAA/tCr within 
an 8-week treatment period indicates that MDD is more 
likely to be associated with neuronal dysfunction rather than 
neuronal loss [32, 33]. We found that significant correlations 
with percent changes of HAMD-17 scores between baseline 
and after MBCT treatment were found only for NAA/tCr 
levels in the left ACC, suggesting that NAA/tCr is a good 
marker for evaluating response to therapy.
The mI is predominately located within astrocytes and is 
a precursor for the phosphatidylinositol second-messenger 
system, which is also presumed to act as an osmoregula-
tor. Significantly decreased mI/tCr levels were previously 
reported in the frontal lobe in patients with MDD [29, 34], 
but there have been limited studies of these chemicals in 
the basal ganglia and insular cortex. The insula plays a role 
in consciousness and subjective feelings [35], and studies 
in MDD using functional MRI (fMRI) have detected abnor-
mal interoceptive activity within this region [36]. In our 
study, decreased mI/tCr was found in the insula in MDD 
relative to controls, which may indicate glial dysfunction 
and/or a reduced number of glial cells in patients with 
MDD [32, 33]. HAMD-17 scores at baseline were signif-
icantly correlated with mI/tCr in the insula and putamen, 
suggesting that mI/tCr may be associated with the severity 
of depression.
Glu is a main excitatory neurotransmitter in the brain 
and is converted to Gln by the reabsorption by neurons or 
reuptake by astrocytes in order to avoid excitotoxicity. It is 
difficult to separate Glu from Gln in the short TE spectra at 
3T, and Glx is typically designated as the sum of Glu and 
Gln peaks, with Glu as the majority component. A previous 
study found that Glx was lower in the dorsolateral prefron-
tal cortex (DLPFC) of MDD patients compared to healthy 
controls [37] and that Glu was increased in responders after 
treatment with 10 days of high-frequency transcranial mag-
netic stimulation (TMS) [38]. Although Glu/tCr in the left 
caudate at baseline was not significantly different than that 
in controls in our study (p = 0.051), it returned to normal 
levels after the 8-week treatment with MBCT. Gln is also 
a precursor for GSH, an antioxidant that prevents damage 
from reactive oxygen species. The role of GSH in MDD 
has not been widely studied. A previous study showed no 
significant correlation between GSH and depression or 
mania for patients with bipolar disorder [39]. Our findings 
of decreased GSH/tCr in insula and putamen indicate that 
GSH may play an important role in MDD.
GABA is a main inhibitory neurotransmitter within the 
brain. Previous studies reported lower GABA in the occipi-
tal cortex in MDD patients [40] and an increase in GABA 
with antidepressant treatment [41]. Reduction in GABA 
is possibly due to impaired GABAergic function and/or 
decreased GABA synthesis [42]. The occipital cortex was 
not analyzed in our study because it was not covered by the 
excitation slab. Although decreased GABA was previously 
reported in ACC [43], there were no significant differences 
in GABA/tCr in ACC in our study.
This study supports the effectiveness of the MBCT treat-
ment as a monotherapy for acute MDD and the effectiveness 
of H-1 MRSI to detect metabolite changes associated with 
successful MBCT treatment for MDD. Although the number 
of patients was relatively small, a number of key results that 
are consistent with our understanding of brain chemistry were 
obtained. Another limitation is that the significant changes 
in metabolite ratios could have been caused by alteration in 
tCr level rather than in other metabolites. The tCr, which has 
peaks at 3.0 and 3.9 ppm, includes Cr and phosphocreatine, 
which are involved in adenosine triphosphate (ATP) metab-
olism. Although some previous studies found no significant 
differences in tCr in patients with MDD [28], others reported 
a significant increase in tCr compared to controls [34]. Imple-
menting and adding a fast MRSI acquisition for unsuppressed 
water may be useful to better understand the roles of tCr in 
MDD, as well as the other metabolites that were observed dif-
ferent in this study. However, our results suggest that using 
3D MRSI at 7T in conjunction with metabolite ratios may 
be a time-efficient strategy for differentiating patients from 
healthy controls and following changes due to treatment.
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Conclusion
In conclusion, results of our study demonstrate differences 
in tCho/tCr, NAA/tCr, Glu/tCr, mI/tCr, GABA/tCr, and 
GSH/tCr in patients with MDD compared to healthy con-
trols and demonstrated changes in these ratios associated 
with MBCT treatment and reduction in depression sever-
ity. Regional differences in metabolite ratios also existed 
in patients with MDD. These results reflect the complexity 
of biochemical changes associated with disease processes 
and treatment effects. Future studies in a larger randomized 
controlled study population will be helpful for interpreting 
changes in metabolite ratios and understanding how thera-
peutic interventions impact MDD. Such information could 
also be valuable for determining at an early stage whether 
patients are responding to therapy or whether a new treat-
ment strategy should be considered.
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